Evolent Health, Inc $EVH Shares Acquired by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Evolent Health, owning approximately 1,023,077 shares valued at $9.69 million, reflecting an 11.3% boost in the first quarter.
• Evolent Health reported an earnings per share (EPS) of ($0.10) for the last quarter, missing estimates and experiencing a 31.3% decline in revenue year-over-year.
• Analysts have set a consensus target price of $17.93 for Evolent Health, with most ratings being positive, including twelve "Buy" ratings.

Charles Schwab Investment Management Inc. lifted its position in shares of Evolent Health, Inc (NYSE:EVH - Free Report) by 11.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,023,077 shares of the technology company's stock after buying an additional 104,085 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.88% of Evolent Health worth $9,689,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Citizens Financial Group Inc. RI grew its holdings in shares of Evolent Health by 36.0% during the first quarter. Citizens Financial Group Inc. RI now owns 21,400 shares of the technology company's stock worth $203,000 after buying an additional 5,668 shares in the last quarter. Raiffeisen Bank International AG grew its holdings in shares of Evolent Health by 33.3% during the first quarter. Raiffeisen Bank International AG now owns 120,000 shares of the technology company's stock worth $1,152,000 after buying an additional 30,000 shares in the last quarter. US Bancorp DE grew its holdings in shares of Evolent Health by 291.0% during the first quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock worth $49,000 after buying an additional 3,835 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Evolent Health by 85.3% during the first quarter. XTX Topco Ltd now owns 43,208 shares of the technology company's stock worth $409,000 after buying an additional 19,887 shares in the last quarter. Finally, Banque Cantonale Vaudoise purchased a new stake in shares of Evolent Health during the first quarter worth about $25,000.

Analyst Upgrades and Downgrades

EVH has been the subject of a number of recent research reports. Truist Financial lifted their price target on shares of Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Needham & Company LLC reissued a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a research report on Tuesday, May 13th. JMP Securities reissued a "market outperform" rating and issued a $13.00 target price on shares of Evolent Health in a research report on Friday, June 20th. Piper Sandler raised their target price on shares of Evolent Health from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, UBS Group raised their target price on shares of Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Evolent Health presently has a consensus rating of "Buy" and an average price target of $18.07.

Evolent Health Trading Down 0.1%

EVH stock traded down $0.01 during midday trading on Friday, reaching $9.63. 1,367,209 shares of the company's stock traded hands, compared to its average volume of 3,772,439. The company has a market capitalization of $1.13 billion, a P/E ratio of -5.98 and a beta of 0.73. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01. Evolent Health, Inc has a fifty-two week low of $7.06 and a fifty-two week high of $32.35. The business has a 50-day moving average price of $10.16 and a two-hundred day moving average price of $9.54.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). The business had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The company's quarterly revenue was down 31.3% on a year-over-year basis. During the same period last year, the firm earned $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. Equities research analysts forecast that Evolent Health, Inc will post 0.08 EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.